Search clinical trials for: PD-1 inhibitor

Total 74952 results

Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Jonsson Comprehensive Cancer Center
Bayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)

Terminated

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Stage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditions

United States
Shi Ming

Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital... and other collaborators

Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Hepatocellular Carcinoma

China
Pfizer

Completed

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Canada, United States, France, Denmark, Finland, Germany
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer
Zhejiang University
Shandong Cancer Hospital and Institute; First Hospital of China Medical University and other collaborators

Recruiting

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma | Adjuvant Therapy

China
Shixiu Wu

Recruiting

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Pancreatic Cancer

China
Sun Yat-sen University
Fudan University; Liaoning Tumor Hospital & Institute

Active, not recruiting

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Colorectal Carcinoma

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Unknown

JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Shanghai Zhongshan Hospital

Unknown

Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Actelion

Terminated

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Pulmonary Hypertension

United States
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
Centre hospitalier de l'Université de Montréal...

Completed

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

Non-small Cell Lung Cancer Metastatic | Cryotherapy Effect

Canada
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Innate Pharma
AstraZeneca

Completed

Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States, France
CellSight Technologies, Inc.
Stanford University

Completed

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck

United States
Sun Yat-sen University

Completed

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Gastric Cancer Stage IV | EBV

China
Johnson & Johnson Healthcare Products Division...

Completed

Safety Study of a Sensitive Sensual Touch and Personal Lubricant

Inadequate Lubrication

United States
Sichuan University

Recruiting

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

NSCLC | PD-1 Inhibitor | Stereotactic Body Radiotherapy | Low Dose Radiotherapy

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

Safety Issues | Effect Increased
Bristol-Myers Squibb

Terminated

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Cancer

United States
Anwaar Saeed
AstraZeneca; Exelixis

Active, not recruiting

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Adenocarcinoma

United States
M.D. Anderson Cancer Center

Completed

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Sun Yat-sen University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma (PLATINUM)

Nasopharyngeal Carcinoma

China
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Phase I Biomarker Study (BMS-936558)

Renal Cell Carcinoma

United States, France, Spain
Assaf-Harofeh Medical Center

Unknown

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Soft Tissue Sarcoma | Osteosarcoma | Chondrosarcoma | Bone Sarcoma | Desmoplastic Small Round Cell Tumor | Gastrointestinal Stromal Sarcoma | Ewing's Tumor Metastatic | Ewing's Tumor Recurrent
Cancer Institute and Hospital, Chinese Academy...
The First Affiliated Hospital with Nanjing Medical University; Fujian Cancer... and other collaborators

Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Esophageal Neoplasms

China
The Methodist Hospital Research Institute
Pfizer

Recruiting

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE)

Urothelial Carcinoma Bladder

United States
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China
Amgen

Recruiting

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Small Cell Lung Cancer (SCLC)

China, United States, Australia, Netherlands, Taiwan, Spain, Canada, Korea, Republic of, Turkey, Israel, Austria, Japan, France, United Kingdom, Germany, Belgium, Denmark, Czechia, Switzerland, Italy, Hungary, Ireland, Argentina, Brazil, Malays... and more
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
University of California, San Francisco
Pfizer

Terminated

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma (PD0332991)

Glioblastoma | Gliosarcoma | Anaplastic Astrocytoma

United States
Sun Yat-sen University

Recruiting

The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites

Malignant Ascites

China
Fudan University
Anyang Tumor Hospital

Not yet recruiting

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Colon Cancer

China
Beijing 302 Hospital

Recruiting

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer

Endometrial Cancer

China
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
The University of Queensland
The HOME Network; Australia and New Zealand Dialysis and Transplant Registry; New Zealand Peritoneal Dialysis Registry

Active, not recruiting

Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial (TEACH-PD)

Kidney Disease, Chronic | Peritoneal Dialysis Catheter Exit Site Infection | Peritoneal Dialysis Catheter-Associated Peritonitis | Peritoneal Dialysis Catheter Tunnel Infection

Australia, New Zealand
Actelion

Terminated

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension (INHALE-15)

Pulmonary Arterial Hypertension

United States
RenJi Hospital
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Recruiting

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

China
Hassane M. Zarour, MD
Merck Sharp & Dohme LLC; Melanoma Research Alliance

Completed

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Melanoma

United States
Yancheng First People's Hospital

Recruiting

Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors

Solid Tumors

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Efficacy | Safety
Jounce Therapeutics, Inc.

Completed

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Sun Yat-sen University

Unknown

A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer

Colorectal Cancer Stage III

China

Search clinical trials for: PD-1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations